NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Canton Strategic Holdings, Inc. (CNTN) Stock Analysis

Canton Strategic Holdings, Inc. (CNTN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

CNTN

$1.93

+$0.20 (+11.56%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CNTN with… →

CNTN Key Statistics

As of Oct 21, 2026
Trading
Open
$1.80
Previous Close
$1.73
Day's Range
1.80–1.97
52-Week Range
1.66–6.89
Volume
839.18K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.48
Valuation
Market Cap
$137.85M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
92.15
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.10
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$35.92M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
79.68M
1-Year Return
−35.45%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
769.22K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, CNTN closed at $1.93, −35.45% over 1 year.

Canton Strategic Holdings, Inc. (CNTN) has a market capitalization of $137.85M.

In fiscal 2025, CNTN reported revenue of $0.00.

CNTN Stock Return by Calendar Year

Canton Strategic Holdings, Inc. (CNTN) return since Jan 2022: what $10,000 became

1 year
$10,000 $6,455
−35.45%
3 years
$10,000 $284
−97.16%
Since Jan 2022
$10,000 $15
−99.85%

If you had invested $10,000 in Canton Strategic Holdings, Inc. (CNTN) at the close on January 12, 2022, the earliest close on record here, it would have been worth $15 at the close on October 21, 2026: −99.85% in total, −74.48% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−36.30%
2025+49.26%
2024−73.41%
2023−94.78%
2022−88.79%

As of October 21, 2026.

CNTN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$35.92M—
2024$0.00−$12.20M—
2023$0.00−$9.32M—
2022$0.00−$8.47M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$20.11M−$35.92M—
2024$0.00—−$12.43M−$12.20M—
2023$0.00—−$9.46M−$9.32M—
2022$0.00—−$6.88M−$8.47M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CNTN Valuation vs Biotechnology Median

Median of 608 stocks
MetricCNTNBiotechnology medianvs median
P/S ratio92.1513.306.9x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Canton Strategic Holdings, Inc. (CNTN) at $137.85M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 12.

Over the past 52 weeks the price has ranged from $1.66 to $6.89. The most recent close on file for CNTN is $1.93, dated October 21, 2026. That is +$0.20 (+11.56%) against the previous close. The latest close sits 16.13% above that 52-week low.

Financial Health

In fiscal 2025, Canton Strategic Holdings, Inc. reported revenue of $0.00. The same year closed with a net loss of $35.92M. Earnings per share on a trailing basis come to −0.1.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 92.15 times revenue. On price-to-sales that is 6.9 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.48. Annualized volatility over the trailing 4 years is 175.29%. Over the trailing twelve months the total return is −35.45%. Across 3 years the annualized return works out at −69.48%.

Growth & Income

No dividend is on file for CNTN.

The strongest complete calendar year on file is 2025 at +49.26%; the weakest is 2023 at −94.78%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the total return is −36.30%.

Peer Comparison

Canton Strategic Holdings, Inc. (CNTN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Canton Strategic Holdings, Inc. CNTN $137.85M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Canton Strategic Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc. focuses on advancing institutional blockchain adoption and digitizing financial markets in the United States. The company operates as a validator and super validator on the Canton Network, which provides validation and liveness services to the network. It also provides locking-as-a-service (LaaS) to Canton Network super validators and featured applications, which locks its own Canton Coin (CC) on a customer's behalf while retaining legal and beneficial ownership. In addition, the company invests in the Canton ecosystem. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is based in New York, New York.

Visit website →